In 2022, the U.S. Food and Drug Administration approved a novel dual immunotherapy of relatlimab, a lymphocyte activation gene-3 (LAG-3) inhibitor in combination with nivolumab for patients with unresectable or metastatic melanoma. The gene discussed is LAG3; the disease is metastatic melanoma.